326 related articles for article (PubMed ID: 25195923)
1. Increasing participation in colorectal cancer screening: results from a cluster randomized trial of directly mailed gFOBT kits to previous nonresponders.
Tinmouth J; Patel J; Austin PC; Baxter NN; Brouwers MC; Earle C; Levitt C; Lu Y; Mackinnon M; Paszat L; Rabeneck L
Int J Cancer; 2015 Mar; 136(6):E697-703. PubMed ID: 25195923
[TBL] [Abstract][Full Text] [Related]
2. Directly Mailing gFOBT Kits to Previous Responders Being Recalled for Colorectal Cancer Screening Increases Participation.
Tinmouth J; Patel J; Austin PC; Baxter NN; Brouwers MC; Earle CC; Levitt C; Lu Y; MacKinnon M; Paszat L; Rabeneck L
J Can Assoc Gastroenterol; 2020 Oct; 3(5):197-203. PubMed ID: 32905094
[TBL] [Abstract][Full Text] [Related]
3. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
[TBL] [Abstract][Full Text] [Related]
5. Two randomized controlled trials for colorectal cancer screening invitations developed using a behavioral science approach.
Tinmouth J; Llovet D; Sutradhar R; Tsiplova K; Roushani J; Lee A; Hader J; Rabeneck L; Paszat L
Prev Med; 2022 Feb; 155():106918. PubMed ID: 34953810
[TBL] [Abstract][Full Text] [Related]
6. Predictors of repeat participation in the NHS bowel cancer screening programme.
Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
Br J Cancer; 2015 Jan; 112(1):199-206. PubMed ID: 25429524
[TBL] [Abstract][Full Text] [Related]
7. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
[TBL] [Abstract][Full Text] [Related]
8. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
[TBL] [Abstract][Full Text] [Related]
9. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use.
Santare D; Kojalo I; Huttunen T; Rikacovs S; Rucevskis P; Boka V; Leja M
Eur J Gastroenterol Hepatol; 2015 May; 27(5):536-43. PubMed ID: 25806603
[TBL] [Abstract][Full Text] [Related]
10. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
Brenner H; Hoffmeister M; Birkner B; Stock C
Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
[TBL] [Abstract][Full Text] [Related]
11. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
Van Roosbroeck S; Hoeck S; Van Hal G
Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
[TBL] [Abstract][Full Text] [Related]
12. Using physician-linked mailed invitations in an organised colorectal cancer screening programme: effectiveness and factors associated with response.
Tinmouth J; Baxter NN; Paszat LF; Rabeneck L; Sutradhar R; Yun L
BMJ Open; 2014 Mar; 4(3):e004494. PubMed ID: 24622950
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Doctor's Invitation on Participation in Colorectal Cancer Screening: A Cluster Randomized Trial.
Barthe J; Perrodeau E; Gilberg S; Ravaud P; Ghasarossian C; Marchand-Buttin F; Deyra J; Falcoff H
Am J Med; 2015 Sep; 128(9):1024.e1-7. PubMed ID: 25908395
[TBL] [Abstract][Full Text] [Related]
14. High test positivity and low positive predictive value for colorectal cancer of continued faecal occult blood test screening after negative colonoscopy.
Brown JP; Wooldrage K; Wright S; Nickerson C; Cross AJ; Atkin WS
J Med Screen; 2018 Jun; 25(2):70-75. PubMed ID: 28467146
[TBL] [Abstract][Full Text] [Related]
15. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study.
Denis B; Gendre I; Perrin P
J Med Screen; 2015 Jun; 22(2):76-82. PubMed ID: 25576338
[TBL] [Abstract][Full Text] [Related]
16. The impact of stratifying by family history in colorectal cancer screening programs.
Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
[TBL] [Abstract][Full Text] [Related]
17. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
18. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.
Church TR; Yeazel MW; Jones RM; Kochevar LK; Watt GD; Mongin SJ; Cordes JE; Engelhard D
J Natl Cancer Inst; 2004 May; 96(10):770-80. PubMed ID: 15150305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
